1 The retractions came only a few months after BioMed Central.

A third reason could be that journals and publishers are multinational increasingly. In the past, the editor and editorial panel of a journal knew both scientific field it covered and the people employed in it, but it’s almost impossible to become sufficiently well connected when both editors and submissions come from all over the world. Having authors suggest the best reviewers may therefore look like a good idea. In the aftermath of the recent scandals involving fake peer reviewers, many journals have decided to carefully turn off the reviewer-suggestion option on their manuscript-submission systems.Enrollment will be stopped and patients will be studied off of the study drug. The lead investigators will complete a complete evaluation of the available data established and the results will be made public. ‘We remain focused on the development of apixaban in additional patient populations,’ said Brian Daniels, M.D., senior vice president, Global Development and Medical Affairs, Bristol-Myers Squibb. ‘We are centered on the rolling submission of data for preventing stroke in sufferers with atrial fibrillation who are anticipated or demonstrated to be unsuitable for treatment with warfarin to the Food and Drug Administration and the application to the European Medicines Company for venous thromboembolism prevention. Other ongoing research investigating apixaban in different patient populations are being monitored by independent data monitoring committees and are continuing.’ ‘Our recommendation to discontinue APPRAISE-2 problems only the populace of high-risk ACS patients receiving anti-platelet therapy signed up for APPRAISE-2,’ said Robert Harrington, M.D., Duke Clinical Study Institute, and co-seat of the APPRAISE-2 Steering Committee.